Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy

Mauro Marzorati, Simone Porcelli, Giuseppe Bellistri, Lucia Morandi, Bruno Grassi

Research output: Contribution to journalArticle

Abstract

Enzyme replacement therapy (ERT) has recently became available for patients with glycogen storage disease type II. Previous studies have demonstrated clinical efficacy of enzyme replacement therapy, however, data on physiological variables related to exercise tolerance are scarce. Four glycogen storage disease type II late-onset patients (45±6years) performed an incremental exercise on a cycle ergometer, up to voluntary exhaustion, before (BEFORE) and after 12months of ERT (AFTER). Peak workload, oxygen uptake, heart rate, cardiac output (by impedance cardiography) and vastus lateralis oxygenation indices (by continuous-wave near-infrared spectroscopy, NIRS) were determined. Peak workload and oxygen uptake values significantly increased during ERT (54±30 vs. 63±31 watt, and 17.2±4.4 vs. 19.7±3.5ml/kg/min, respectively, in BEFORE vs. AFTER). On the other hand, for both peak cardiac output (12.3±5.3 vs. 14.8±4.5L/min) and the NIRS-determined peak skeletal muscle fractional O2 extraction, expressed as a percentage of the maximal values during a transient limb ischemia (30±39% vs. 38±28%), the observed increases were not statistically significant. Our findings suggest that in glycogen storage disease type II patients enzyme replacement therapy is associated with a mild improvement of exercise tolerance. The findings need to be validated during a longer follow-up on a larger group of patients.

Original languageEnglish
JournalNeuromuscular Disorders
Volume22
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Dec 1 2012

Fingerprint

Glycogen Storage Disease Type II
Enzyme Replacement Therapy
Exercise
Exercise Tolerance
Near-Infrared Spectroscopy
Workload
Cardiac Output
Impedance Cardiography
Oxygen
Quadriceps Muscle
Skeletal Muscle
Ischemia
Extremities
Heart Rate

Keywords

  • Cardiac output
  • Glycogen storage disease type II
  • Near-infrared spectroscopy
  • Oxidative metabolism

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Genetics(clinical)
  • Neurology

Cite this

Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy. / Marzorati, Mauro; Porcelli, Simone; Bellistri, Giuseppe; Morandi, Lucia; Grassi, Bruno.

In: Neuromuscular Disorders, Vol. 22, No. SUPPL. 3, 01.12.2012.

Research output: Contribution to journalArticle

Marzorati, Mauro ; Porcelli, Simone ; Bellistri, Giuseppe ; Morandi, Lucia ; Grassi, Bruno. / Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy. In: Neuromuscular Disorders. 2012 ; Vol. 22, No. SUPPL. 3.
@article{d39a3028363441a5af0e882d219db795,
title = "Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy",
abstract = "Enzyme replacement therapy (ERT) has recently became available for patients with glycogen storage disease type II. Previous studies have demonstrated clinical efficacy of enzyme replacement therapy, however, data on physiological variables related to exercise tolerance are scarce. Four glycogen storage disease type II late-onset patients (45±6years) performed an incremental exercise on a cycle ergometer, up to voluntary exhaustion, before (BEFORE) and after 12months of ERT (AFTER). Peak workload, oxygen uptake, heart rate, cardiac output (by impedance cardiography) and vastus lateralis oxygenation indices (by continuous-wave near-infrared spectroscopy, NIRS) were determined. Peak workload and oxygen uptake values significantly increased during ERT (54±30 vs. 63±31 watt, and 17.2±4.4 vs. 19.7±3.5ml/kg/min, respectively, in BEFORE vs. AFTER). On the other hand, for both peak cardiac output (12.3±5.3 vs. 14.8±4.5L/min) and the NIRS-determined peak skeletal muscle fractional O2 extraction, expressed as a percentage of the maximal values during a transient limb ischemia (30±39{\%} vs. 38±28{\%}), the observed increases were not statistically significant. Our findings suggest that in glycogen storage disease type II patients enzyme replacement therapy is associated with a mild improvement of exercise tolerance. The findings need to be validated during a longer follow-up on a larger group of patients.",
keywords = "Cardiac output, Glycogen storage disease type II, Near-infrared spectroscopy, Oxidative metabolism",
author = "Mauro Marzorati and Simone Porcelli and Giuseppe Bellistri and Lucia Morandi and Bruno Grassi",
year = "2012",
month = "12",
day = "1",
doi = "10.1016/j.nmd.2012.10.017",
language = "English",
volume = "22",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Ltd",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy

AU - Marzorati, Mauro

AU - Porcelli, Simone

AU - Bellistri, Giuseppe

AU - Morandi, Lucia

AU - Grassi, Bruno

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Enzyme replacement therapy (ERT) has recently became available for patients with glycogen storage disease type II. Previous studies have demonstrated clinical efficacy of enzyme replacement therapy, however, data on physiological variables related to exercise tolerance are scarce. Four glycogen storage disease type II late-onset patients (45±6years) performed an incremental exercise on a cycle ergometer, up to voluntary exhaustion, before (BEFORE) and after 12months of ERT (AFTER). Peak workload, oxygen uptake, heart rate, cardiac output (by impedance cardiography) and vastus lateralis oxygenation indices (by continuous-wave near-infrared spectroscopy, NIRS) were determined. Peak workload and oxygen uptake values significantly increased during ERT (54±30 vs. 63±31 watt, and 17.2±4.4 vs. 19.7±3.5ml/kg/min, respectively, in BEFORE vs. AFTER). On the other hand, for both peak cardiac output (12.3±5.3 vs. 14.8±4.5L/min) and the NIRS-determined peak skeletal muscle fractional O2 extraction, expressed as a percentage of the maximal values during a transient limb ischemia (30±39% vs. 38±28%), the observed increases were not statistically significant. Our findings suggest that in glycogen storage disease type II patients enzyme replacement therapy is associated with a mild improvement of exercise tolerance. The findings need to be validated during a longer follow-up on a larger group of patients.

AB - Enzyme replacement therapy (ERT) has recently became available for patients with glycogen storage disease type II. Previous studies have demonstrated clinical efficacy of enzyme replacement therapy, however, data on physiological variables related to exercise tolerance are scarce. Four glycogen storage disease type II late-onset patients (45±6years) performed an incremental exercise on a cycle ergometer, up to voluntary exhaustion, before (BEFORE) and after 12months of ERT (AFTER). Peak workload, oxygen uptake, heart rate, cardiac output (by impedance cardiography) and vastus lateralis oxygenation indices (by continuous-wave near-infrared spectroscopy, NIRS) were determined. Peak workload and oxygen uptake values significantly increased during ERT (54±30 vs. 63±31 watt, and 17.2±4.4 vs. 19.7±3.5ml/kg/min, respectively, in BEFORE vs. AFTER). On the other hand, for both peak cardiac output (12.3±5.3 vs. 14.8±4.5L/min) and the NIRS-determined peak skeletal muscle fractional O2 extraction, expressed as a percentage of the maximal values during a transient limb ischemia (30±39% vs. 38±28%), the observed increases were not statistically significant. Our findings suggest that in glycogen storage disease type II patients enzyme replacement therapy is associated with a mild improvement of exercise tolerance. The findings need to be validated during a longer follow-up on a larger group of patients.

KW - Cardiac output

KW - Glycogen storage disease type II

KW - Near-infrared spectroscopy

KW - Oxidative metabolism

UR - http://www.scopus.com/inward/record.url?scp=84870042338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870042338&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2012.10.017

DO - 10.1016/j.nmd.2012.10.017

M3 - Article

C2 - 23182645

AN - SCOPUS:84870042338

VL - 22

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - SUPPL. 3

ER -